— Dr. Gaggar is a seasoned industry executive with extensive infectious disease expertise and a proven track record of successfully leading early and clinical-stage antiviral programs —
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB) is a biotechnology company developing innovative antiviral therapies for serious viral diseases. Today it was announced that Anuj Gaggar, MD, PhD, has joined the company as Chief Medical Officer. Dr. Gaggar is an infectious disease expert and experienced executive whose experience focuses on the development of new treatments for viral diseases, including chronic hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatitis D Viral (HDV) infection.
“We are pleased to have Dr. Gaggar join Assembly Bio’s leadership team at an extremely important time for the organization,” said Jason Okazaki, CEO and President. “Anuj’s depth and breadth of experience in successfully developing life-changing antiviral therapies will be instrumental in executing our plan to bring four combination compounds into the clinic in 2024 with the goal of improving outcomes for patients with herpes viruses and viral hepatitis. Life. “
“I am excited to join Assembly Bio as we work to bring next-generation antiviral treatments to patients,” said Dr. Gaggar. “These programs are targeting clinical entry next year – two long-acting helicase primase inhibitors against herpes simplex virus, a next-generation capsid assembly modulator ABI-4334 for the treatment of HBV, and an orally bioavailable HDV Enter inhibitor ABI-6250 – with the potential to provide improved treatment options to patients in areas of high unmet medical need. “I look forward to working with Assembly Bio’s strong scientific organization to advance these programs. “
Dr. Gaggar joins Arrive Bio, a privately held early-stage biotechnology company, where he co-founded and served as CEO. Prior to joining Arrive Bio, Dr. Gaggar served for nearly 10 years as a senior member of the Gilead Sciences clinical research team, responsible for scientific clinical development strategy and execution. As Vice President of Clinical Research, he led the hepatitis B therapeutic development program, including the design and execution of global clinical trials, and was project leader for early development programs and hepatitis B translational research. Dr. Gaggar also contributed to registration studies for Vemlidy® (tenofovir alafenamide), Sovaldi® (sofosbuvir) and Veklury® (remdesivir) and serves as program team leader for a portfolio of approved HCV therapeutics. He has published more than 95 publications extensively in the fields of basic and clinical virology.
Dr. Gajjar is a clinical fellow in infectious diseases at the University of California, San Francisco, where he serves as chief resident. He received his MD and PhD degrees from the University of Washington and his BA in chemistry from Stanford University.
About Assembly Biosciences
Assembly Biosciences is a biotechnology company developing innovative small molecule antiviral therapies designed to change the path of serious viral diseases and improve the lives of patients around the world. Led by a team of proven leaders in virology drug development, Assembly Bio is committed to improving outcomes for patients suffering the serious, chronic effects of herpesvirus, hepatitis B virus (HBV) and hepatitis delta virus (HDV) infections. For more information, visit assemblybio.com.
forward-looking statements
The information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include: Assembly Bio’s ability to realize the potential benefits of the collaboration with Gilead, including all financial aspects of the collaboration and equity investment; Assembly Bio’s ability to initiate and complete the therapies involved in its collaboration within the currently expected timeframe or at all; Clinical studies of product candidates, including studies contemplated by Assembly Bio’s collaboration with Gilead; The occurrence of any events, changes or other circumstances that may result in the termination of Assembly Bio’s collaboration with Gilead; Safety and efficacy data from clinical or non-clinical studies Further development of Assembly Bio’s product candidates may not be guaranteed; clinical and non-clinical data presented at meetings may not differentiate Assembly Bio’s product candidates from those of other companies; results from non-clinical studies may not be representative of those in a clinical setting disease behavior, and may not predict the results of clinical studies; and other risks identified from time to time in Assembly Bio’s reports filed with the U.S. Securities and Exchange Commission (SEC). We urge you to consider statements that include words such as may, will, will, could, should, could, believe, hope, estimate, project, potential, expect, plan, anticipate, intend, continue, predict, design, target or the negative of these words or other similar words that are uncertain and forward-looking. Assembly Bio intends that such forward-looking statements will be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Additional information regarding Assembly Bio’s risks and uncertainties are more fully detailed under the heading “Risk Factors” in Assembly Bio’s filings with the SEC, including its most recent Annual Report on Form 10-K, 10- Quarterly reports on Form Q and current reports on Form 10-Q. Form 8-K. Except as required by law, Assembly Bio undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact information
Investors and businesses:
Shannon Ryan
Senior Vice President, Investor Relations, Corporate Affairs and Alliance Management
(415)738-2992
sryan@assemblybio.com
half:
Sam Brown Company
Hannah Harder
(805)338-4752
ASMBMedia@sambrown.com
